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Background: Protein cage nanoparticles are promising nanoplatform candidates for efficient delivery systems
of diagnostics and/or therapeutics because of their uniform size and structure as well as high biocompatibility
and biodegradability. Encapsulin protein cage nanoparticle is used to develop a cell-specific targeting optical
nanoprobe.
Results: FcBPs are genetically inserted and successfully displayed on the surface of encapsulin to form FcBP-encapsulin.
Selectively binding of FcBP-encapsulin to SCC-7 is visualized with fluorescent microscopy.
Conclusions: Encapsulin protein cage nanoparticle is robust enough to maintain their structure at high temperature and
easily acquires multifunctions on demand through the combination of genetic and chemical modifications.
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Conventional drugs and diagnostic probes tend to dif-
fuse rapidly and get distributed throughout the body
easily upon systematic administration [1]. Non-targeted
treatments generally cause detrimental side effects in
normal cells and tissues and the reduction of the effect-
iveness of the treatment [2]. The targeted delivery of
diagnostic or/and therapeutic reagents to desired sites is
a challenging, but promising, task for the early diagnosis
of diseases as well as effective and localized treatment of
diseases.
A variety of inorganic or organic nanoparticles, includ-
ing metal nanoparticles [3,4], micelles [5,6], polymers
[7-9], liposomes [9-11], and protein cages [1,12], have
been investigated as efficient delivery vehicles for diag-
nostic or/and therapeutic reagents because they have
great potential to improve the pharmacological proper-
ties of drugs and maximize the localized treatment of
diseases [13]. The manipulation of size and surface of
nanoparticles increase their accessibility to disease sites
and circulation time in the bloodstream due to their* Correspondence: sabsab7@unist.ac.kr
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unless otherwise stated.enhanced permeability and retention (EPR) effect; this
improves the biodistribution of drugs [14,15].
Protein cages, such as ferritins [12,16-19], viral capsids
[17,20-24], lumazine synthase [20,25,26], and encapsulin
[27], are promising nanoplatform candidates for efficient
delivery systems of diagnostics and/or therapeutics be-
cause they have uniform size and structure as well as
high biocompatibility and biodegradability [1]. Protein
cages are spontaneously self-assembled from multiple
copies of one or a few types of protein subunits in a pre-
cisely controlled manner. In addition, they can be ma-
nipulated genetically and chemically to have a desired
function, using a rational design based on atomic reso-
lution structural information.
Encapsulin, a novel protein cage nanoparticle isolated
from thermophile Thermotoga maritima, is assembled
from 60 copies of identical 31 kDa monomers having a
thin and icosahedral T = 1 symmetric cage structure
with interior and exterior diameters of 20 and 24 nm,
respectively [28]. Although the exact function of encap-
sulin in T. maritima is not clearly understood yet, its
crystal structure has been recently solved and its func-
tion was postulated as a cellular compartment that
encapsulates proteins such as DyP (Dye decolorizing
peroxidase) and Flp (Ferritin like protein) which areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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implied that encapsulin has a large enough central cavity
(20 nm in inner diameter) to encapsulate a large
amount of therapeutic and/or diagnostic reagents and
we recently constructed a heat stable encapsulin vari-
ant through genetic engineering and demonstrated the
utility of engineered encapsulin as a versatile drug
delivery nanoplatform.
In the present study, we genetically engineered a novel
protein cage nanoparticle, encapsulin, to display cell-
specific targeting peptides (DCAWHLGELVWCT) onto
the surface in a controlled manner and demonstrated its
selective binding to Squamous cell carcinoma (SCC-7)
cell line exclusively.
Methods
Genetic modification of encapsulin and protein cage
purification
We started with a genetically modified encapsulin,
which has only one cysteine per subunit at position
123. Cell targeting peptide with linker (GGGGGGD
CAWHLGELVWCTGGGGG) was inserted into resi-
dues between 138 and 139 of encapsulin by an estab-
lished polymerase chain reaction (PCR) protocol using
pET-30b based plasmids containing genes encoding
encapsulin [20].
Peptide insertion was confirmed by DNA sequencing
and confirmed DNAs were transformed into the compe-
tent E.coli strain BL21 (DE3) and the protein cages were
over-expressed in E.coli. The pelleted E.coli cells from
1.0 L of culture were resuspended in 35 mL of phos-
phate buffer (50 mM sodium phosphate and 100 mM
sodium chloride, pH 6.5). Lysozyme was added and the
solution was incubated for 30 min at 4°C. The suspen-
sion was sonicated for 10 min in 30 s intervals, and
subsequently centrifuged at 12000 g for 1 hr at 4°C.
Encapsulin protein cage was purified by size exclusion
chromatography (SEC) after heat precipitation for 10 min
at 65°C [20].
Quartz crystal microbalance (QCM) measurements
QCM experiments were performed using Q-Sense E4
and standard gold QCM sensors (Q-Sense, Sweden) as
described previously [30]. Briefly, the system was oper-
ated in flow mode with a pump and temperature was
maintained at 25.0 ± 0.1°C. Each sample solution was
introduced to the measurement chamber with a pump
and continuously measured for 3 min prior to the subse-
quent introductions. Protein cages and rabbit IgGs were
introduced at concentrations of approximately 100 μg/
ml and 50 μg/ml, respectively, in phosphate buffer
(50 mM phosphate, 100 mM NaCl, pH 6.5). Resonance
frequencies were measured simultaneously at seven har-
monics (5, 15, 25, 35, 45, 55 and 65 MHz). For clarity,only the normalized frequency of the third overtone is
shown.
Surface plasmon resonance (SPR) analysis
SPR experiments were performed with carboxyl dextran
CM-5 gold chips on a Biacore 3000 device (Biacore AB,
Sweden) at 25 oC using a PBS buffer as a running solu-
tion. Rabbit IgG was coupled to the surface of a CM-5
sensor chip by standard amine-coupling chemistry on
the SPR instrument as described previously, with slight
modifications [31]. Briefly, a mixture of EDC (0.4 M)
and NHS (0.6 M) was injected onto the chip at a flow
rate of 10 μl/min to activate carboxyl groups on the sen-
sor surface and subsequently 20 μg/ml of rabbit IgG was
added at the same flow rate for 7 min. Excess reactive
groups were blocked with 1 M ethanolamine (pH 8.0).
Encapsulin capture by rabbit IgG was examined by ap-
plying various amounts (1, 5, 10, 25, 50, and 100 nM) of
encapsulin (PBS, pH 7.4) to the surface at a flow rate of
30 μl/min.
Mass spectrometry of modified encapsulin protein cage
For ESI-TOF analysis, encapsulin protein cages were
loaded onto the MassPREP Micro-desalting column
(Waters) and eluted with a gradient of 5-95% (v/v)
acetonitrile containing 0.1% formic acid at a flow rate of
500 μL/min. The molecular masses of each species can
be determined from the charges and the observed mass-
to-charge (m/z) ratio values. Mass spectra were acquired
in the range of m/z 500-3000 and deconvoluted using
MaxEnt1 from MassLynx version 4.1 to obtain the aver-
age mass from multiple charge state distributions [20].
Cell culture and confocal fluorescence microscopy
All cell lines in this article were obtained from the
Korean cell line bank (KCLB) and maintained in a humidi-
fied atmosphere of 5% CO2 and 95% air at 37°C. SCC-7
cells were incubated in RPMI 1640 medium with 10%
fetal bovine serum (FBS), 1% penicillin/streptomycin.
MDA-MB-231 and HepG2 cells were incubated in RPMI
1640 medium with 10% FBS, 1% streptomycin. KB cells
were cultured in RPMI1640 medium with L-glutamine
(300 mg/L), 10% FBS, 1% streptomycin, 25 mM HEPES
and 25 mM NaHCO3. Hela cells were incubated in
DMEM medium with 4.5 g/L glucoseand L-glutamine,
10% FBS and 1% streptomycin. Cells were grown on
microscope cover glasses (18 mm Ø) in 12-well culture
plate (SPL, 30012). The cells were fixed with 4% parafor-
maldehyde in PBS and washed 2 times with PBS con-
taining 0.1% Tween 20. The fixed cells were blocked
with 5% BSA, 5% FBS, and 0.5% Tween 20 in PBS at 4°C
for 18 hr and blocking buffer was aspirated. Encapsulin
and FcBP-encapsulin were treated for 20 hr at 4°C. Be-
fore sealing, the cells on the cover glasses were washed
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ages of stained substrates were collected using Olympus
Fluoview FV1000 confocal microscope (Olympus, UOBC).
Results and discussions
Construction of FcBP-presenting encapsulin protein cage
nanoparticles
To use encapsulin protein cage as a nanoplatform for a
targeted delivery vehicle, we genetically introduced a short
peptide (GGGGGGDCAWHLGELVWCTGGGGG) with
extra glycine residues onto the surface loop region of
encapsulin (Figure 1A). This short peptide is known to
have a high affinity to the Fc region of immunoglobulin G
(IgG) originated from rabbit [32] and therefore it is called
Fc-binding peptide (FcBP). Based on the crystal structure
of encapsulin, the loop regions are exposed on the surface
and easily form intra-strand disulfide bonds (underlines in
amino acid sequence) due to their proximal distant in-
duced by the loop configuration (Figure 1A) [33]. FcBPFigure 1 Characterization of the FcBP-Encapsulin. (A) Surface and ribbo
introduce the FcBP is indicated with black dot. The FcBP is represented as v-s
encapsulin (bottom) and FcBP-encapsulin (top). Calculated and observed mol
(bottom) and FcBP-encapsulin (top). (D) Transmission electron microscopic iminsertion was confirmed by DNA sequencing and molecu-
lar mass measurement of subunit of FcBP inserted encap-
sulin protein cages (FcBP-encapsulin).
Purified FcBP-encapsulin was characterized by mass
spectrometry (MS), size exclusion chromatography
(SEC), and transmission electron microscopy (TEM).
Each FcBP-encapsulin subunit exhibited a molecular
mass of 34,135.4 Da, which is well matched with the
predicted molecular mass of 34,137.5 Da (Figure 1B,
top panel). FcBP-encapsulin eluted at the same pos-
ition as encapsulin on SEC, suggesting that FcBP-
encapsulin forms a stable 60-mer cage architecture
(Figure 1C). TEM images of stained FcBP-encapsulin
protein cages confirmed an intact cage architecture
with a uniform size distribution with a diameter of ap-
proximately 25 nm (Figure 1D). These results indicate
that FcBP-encapsulin forms an intact protein cage
architecture without significant changes in size, com-
position, and architecture.n diagram representations of encapsulin (PDB: 3DKT). The position to
haped line. (B) Molecular mass measurements of dissociated subunits of
ecular masses were indicated. (C) Size exclusion profiles of encapsulin
age of negatively stained FcBP-encapsulin with 2% uranyl acetate.
Figure 2 Binding behaviors of FcBP-Encapsulin to antibodies. (A) QCM resonance frequency change (-ΔF) profiles of either encapsulin (dashed
line) or FcBP-encapsulin (solid line) on the gold QCM sensors and subsequent deposition of rabbit IgG on the monolayer of FcBP-encapsulin. Filled and
open arrows indicate the timing of encapsulin variant and rabbit IgG introductions, respectively. Thin arrows indicate the timing of buffer washing. SPR
analyses of FcBP-encapsulin (B) and encapsulin (C) bindings to rabbit IgG immobilized gold SPR sensors. Filled and open arrows indicate the timing of
encapsulin variant introductions and buffer washing, respectively. Inset of (C) is amplified graph of low RU ranges.
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A synthetic cyclic FcBP (DCAWHLGELVWCT) exhib-
ited a high affinity to rabbit IgGs with the value of Kd =
305 nM [32]. In order to test whether inserted FcBPs are
on the surface of encapsulin, we performed real-timeFigure 3 Fluorescent microscopic images. Fluorescent microscopic images
(D-F). Fluorescent microscopic images of Hela cells (G-L) treated with f-encapsu
rows), and merged (right rows) were represented.quartz crystal microbalance (QCM) analysis. Typically,
deposition of molecules on the QCM sensor results in
decreases in resonance frequency (-ΔF) and the extent
of frequency changes are sensitive to the masses of the
deposited molecules [30,34]. We have shown that QCMof SCC-7 cells (A-F) treated with f-encapsulin (A-C) and fFcBP-encapsulin
lin (G-I) and fFcBP-encapsulin (J-L). DAPI (left rows), fluorescein (middle
Figure 4 Fluorescent microscopic images. Fluorescent microscopic images of HepG2 cells (A, D) treated with f-encapsulin (A, B) and fFcBP-
encapsulin (C, D). Fluorescent microscopic images of MDA-MB-231 cells (E, H) treated with f-encapsulin (E, F) and fFcBP-encapsulin (G, H). Fluorescent
microscopic images of KB cells (I, L) treated with f-encapsulin (I, J) and fFcBP-encapsulin (K, L). DAPI (A, C, E, G, I, K) and fluorescein (B, D, F, H, J, L)
were represented.
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interactions. Various types of protein cages, including
ferritins, lumazine synthase, and virus-like particles (VLP),
showed strong binding capability to the gold QCM sensor
and form uniform monolayers without any surface modifi-
cations [30,34]. The resonance frequency value of FcBP-
encapsulin (Figure 2A, solid line, filled arrow) itself was
lower than that of encapsulin (Figure 2A, dashed line,
filled arrow) only probably due to the increase in mass of
the FcBP insertions to encapsulin (24 amino acids, an
approximate 8% increase in mass) (Figure 2A). The
resonance frequency of each sample decreased, plat-
eauing when it reached a certain value. In addition, no
additional changes were observed even with continu-
ous introduction of further sample and subsequent
washing, indicating that the encapsulin had formed a
uniform monolayer regardless of the FcBP insertion
and that there was negligible amount of non-specific
absorption (Figure 2A, thin arrow). Subsequently, we
introduced rabbit IgG solution over the encapsulin- or
FcBP-encapsulin-monolayered QCM sensors and mea-
sured frequency changes in real-time (Figure 2A). Whilethe frequency of FcBP-encapsulin-monolayered QCM
sensor decreased dramatically upon introduction of
rabbit IgG, the frequency of encapsulin-monolayered
QCM sensor remained unchanged (Figure 2A, open
arrow). Extensive washing removed only slight amounts of
non-specifically associated rabbit IgG with most of the ini-
tially bound rabbit IgG remaining bound (Figure 2A, thin
arrow). These results indicated that the inserted FcBPs are
well displayed on the surface of encapsulin and they are
fully accessible for Fc regions of rabbit IgGs to bind. These
data also imply that exterior displayed FcBPs can be used
as ligands for target selective delivery of FcBP-encapsulin.
Next, we examine whether FcBP-encapsulin can
recognize the immobilized targets and selectively bind
to them. To do that, we performed surface plasmon
resonance (SPR) analysis. In contrast to QCM studies,
we first immobilized rabbit IgGs on the surface of an
SPR CM-5 sensor chip [32] and introduced either
FcBP-encapsulin or encapsulin at several concentra-
tions. If the inserted FcBPs are exposed on the surface
of encapsulin and accessible to the biomolecules, they
will selectively bind to the immobilized rabbit IgGs
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on the amounts of introduced FcBP-encapsulin or encapsu-
lin. As we expected, gradual increases in SPR responses
(RU) were observed upon introduction of FcBP-encapsulin
(Figure 2B, filled arrow), with RU values reaching a plateau
at each concentration (Figure 2B, open arrow). Consistent
with previous QCM results, apparent dissociation of FcBP-
encapsulin from the immobilized rabbit IgG was not ob-
served even after extensive buffer washing (Figure 2B).
However, encapsulin did not bind to the immobilized rabbit
IgGs at all (Figure 2C and inset) regardless of the amount
of introduced encapsulin. These results suggest that the
FcBPs displayed on the encapsulin can recognize the
immobilized target, rabbit IgG, and allow to selectively
bind to them and multiple FcBPs on the surface of
FcBP-encapsulin may cooperatively capture the immo-
bilized rabbit IgGs resulting in extremely strong bind-
ing (Figure 2B).
Specific binding of FcBP-encapsulin to the SCC-7 cells
FcBP-encapsulin has only one cysteine per subunit at
position 123 (60 cysteines per cage) which is known to
be chemically active. To attach fluorescent probes to the
FcBP-encapsulin, we treated FcBP-encapsulin with acti-
vated fluorescein-5-maleimide (F5M). F5M-conjugated
FcBP-encapsulin (fFcBP-encapsulin) was separated from
unreacted F5M by SEC, and we confirmed that every
subunit is labeled with one F5M using MS (data not
shown).
To determine whether FcBP-encapsulin can bind a
particular cell selectively, we treated a variety of cell
lines with fFcBP-encapsulin and visualized them with
fluorescent microscopy. F5M-conjugated encapsulin (f-
encapsulin) was also treated in parallel as control. We
first tried SCC-7 cells which overexpress a cell surface
glycoprotein CD44 involved in cell-cell interactions, cell
adhesion and migration. While f-encapsulin did not bind
to SCC-7 cells at all (Figure 3A-C), fFcBP-encapsulin
bound to SCC-7 cells (Figure 3D-F). Fluorescence images
of SCC-7 treated with fFcBP-encapsulin showed cytosolic
accumulation of fFcBP-encapsulin (Figure 3E, F). These
data suggest that FcBP-encapsulin recognizes surface
markers of SCC-7 cells, selectively binds to them, and is
internalized. Furthermore, the pretreatment of SCC-7 cells
with anti-CD44 antibody completely blocked the binding
of FcBP-encapsulin (data not shown). We then chose Hela
cells and treated them with same way of SCC-7 cells. We
did not observe any binding of neither fFcBP-encapsulin
nor f-encapsulin to Hela cells (Figure 3G-L). To inves-
tigate cell selectivity of FcBP-encapsulin further, we
prepared HepG2 hepatocyte cells, MDA-MB-231
breast cancer cells, and KB epithelial cells additionally
and treated them with fEcBP-encapsulin or f-encapsulin.
None of cell lines we prepared showed the evidence ofspecific binding of either fEcBP-encapsulin or f-encapsulin
(Figure 4). Although through studies about surface mole-
cules that FcBP-encapsulin binds to should be done, these
data demonstrate that FcBP-encapsulin selectively recog-
nizes and binds to SCC-7 cells and has a potential to be
used as an efficient molecular imaging probe in vitro.
FcBP-encapsulin has a large internal cavity (20 nm in
diameter) and it can be used for encapsulating chemicals,
nanomaterials, and proteins. Thus, encapsulin has a po-
tential to be used as a modular template for developing a
versatile, multifunctional theranostic system, which has
specific cell targeting ligands and diagnostic and thera-
peutic reagents simultaneously
Conclusions
In this study, we engineered encapsulin protein cage
nanoparticle as a SCC-7 cell targeting optical nanoprobe.
Fc-binding peptide with linker (GGGGGGDCAWHL
GELVWCTGGGGG, FcBP) was introduced onto the
surface loop region of encapsulin. Insertion of FcBPs
and integrity of FcBP-encapsulin were confirmed by
various biophysical methods, including MS, SEC, and
TEM. QCM and SPR analyses demonstrated that FcBP-
encapsulin indeed polyvalently displayed FcBPs on the
surface of encapsulin by monitoring specific binding of
it to rabbit IgG. Fluorescently labeled FcBP-encapsulin
selectively bound to the SCC-7, but not to the Hela,
HepG2, MDA-MB-231 or KB cells as shown by fluores-
cence imaging. Since FcBP-encapsulin is robust and ac-
quire multifunctions on demand, it can be used as a
nanoplatform for developing a multifunctional theranos-
tic system.
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